Full Prescribing Information Contact Us Billing Information

If your patient is covered under

Medical Benefits
Pharmacies must register here to request assistance for their eligible COAGADEX patients covered under medical benefits.
Pharmacy Benefits
If the patient’s primary payer drug claim is billed under pharmacy benefits, submit the claim to the primary payer first. If the patient requires co-pay assistance, submit the balance due to Medmonk as a secondary payer (COB - Coordination of Benefits) using the BIN: 016664, PCN: MEDMONK, and Cardholder ID: MEDMONK
Timely Filing
Claims must be received within 30 days of dispense date. For medical benefits, EOBs must be submitted within 120 days of claim submission.

Payer Sheet
Please use this Payer Sheet if your organization does not already have Medmonk enlisted as a payer.

This program is subject to change or discontinuation by Kedrion Biopharma Inc. at any time, for any reason, and with or without prior notice. This portal is administered by Medmonk for the COAGADEX Co-Pay Support Program.

Indications for COAGADEX

COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children (aged 12 years and above) with hereditary factor X deficiency for:

Limitation of use

Perioperative management of bleeding in major surgery in patients with severe hereditary factor X deficiency has not been studied.

Important Safety Information

COAGADEX is contraindicated in patients with known hypersensitivity to any of the components of the product.

Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately and contact their physician.

The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.

COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.

In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.

Please see full prescribing information for Coagadex.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Coagadex® is a registered trademark of Kedrion Biopharma Inc.
Coagadex is manufactured by Bio Products Laboratory U.S.A., Inc. and distributed by Kedrion Biopharma Inc.